EMERYVILLE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with ...
Bivalent EABR mRNA boosters broaden neutralizing responses to Omicron subvariants by promoting diverse receptor-binding domain epitope targeting, although antibody responses remain partially shaped by ...
Detailed price information for Kyverna Therapeutics Inc (KYTX-Q) from The Globe and Mail including charting and trades.
Creativity and curiosity have always been central to the work of Joshua Moreau, Ph.D., an immunologist whose work at Oregon ...
SAN FRANCISCO and SUZHOU, China, April 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...
T cells, which target infection and disease, can become more effective after a meal. The finding might help improve ...
My father trained as a dermatologist and then became board certified in allergy and immunology the first year that allergy ...
As the immune system weakens with age, scientists have found a way to restore some of its lost strength. By delivering mRNA to the liver, they created a temporary source of immune-boosting signals ...
WHO's approval of the RTS,S/AS01 (Mosquirix) malaria vaccine in 2021 marked a milestone in global public health. It represented not only the first vaccine approved against any parasitic human disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results